Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach

Lian Chen1, Hengmin Cui2,3

  • 1Key Laboratory of Animal Diseases and Environmental Hazards of Sichuan Province, Sichuan Agriculture University, Ya'an 625014, China. lianchen87@163.com.

Insights

Targeting cancer cell glutamine metabolism is a promising therapeutic strategy. Restricting glutamine metabolism inhibits tumor growth by inducing apoptosis, growth arrest, and autophagy, making it an appealing approach for cancer therapy.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Cancer biology

Background:

  • Glutamine metabolism is frequently dysregulated in cancer cells.
  • Glutamine is essential for the proliferation of most cancer cells.
  • Targeting glutamine metabolism offers a potential therapeutic avenue.

Purpose of the Study:

  • To review recent research on glutamine metabolism in cancer.
  • To explore cell death mechanisms induced by targeting glutamine.
  • To discuss the therapeutic potential of glutamine metabolism targeting in cancer therapy.

Main Methods:

  • Review of current scientific literature on glutamine metabolism and cancer.
  • Analysis of studies investigating glutamine transporters and glutaminase inhibitors.
  • Examination of research on the effects of glutamine restriction on tumor growth.

Main Results:

  • Glutamine metabolism is crucial for cancer cell proliferation.
  • Several drugs targeting glutaminase are in development or clinical trials.
  • Glutamine metabolism restriction effectively inhibits tumor growth in vitro and in vivo.
  • Inhibition of tumor growth occurs through apoptosis, growth arrest, and/or autophagy.

Conclusions:

  • Targeting glutamine metabolism is a viable strategy for cancer therapy.
  • Further research into glutamine metabolism and its role in cell death pathways is warranted.
  • Glutamine-targeting drugs show promise for clinical application in oncology.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
758
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.3K